公开(公告)号：US20220356202A1

公开(公告)日：2022-11-10

申请号：US17860468

申请日：2022-07-08

Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng ,  Jian Ding ,  Zhenqing Zhang ,  Zhongping Xiao ,  Xiaoguang Du ,  Xianliang Xin

IPC: C07H15/04 ,  A61P25/28 ,  A61K31/7032 ,  A61K31/715 ,  C08B37/00

Abstract: The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

公开(公告)号：US11464794B2

公开(公告)日：2022-10-11

申请号：US17256853

申请日：2019-06-28

Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng ,  Zhenqing Zhang ,  Yingshen Jin ,  Zhongping Xiao ,  Jian Ding

IPC: A61K31/702 ,  A61P25/28 ,  A61P29/00

Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m′ is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.

公开(公告)号：US11406651B2

公开(公告)日：2022-08-09

申请号：US17256738

申请日：2019-06-28

Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng ,  Xianliang Xin ,  Xiaoguang Du ,  Zhenqing Zhang ,  Jian Ding

IPC: A61K31/702 ,  A61P25/28

Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

公开(公告)号：US20210322449A1

公开(公告)日：2021-10-21

申请号：US17256889

申请日：2019-06-28

Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng ,  Xianliang Xin ,  Zhenqing Zhang ,  Jian Ding

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7016 ,  A61K31/715 ,  A61P3/10

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

公开(公告)号：US20210261539A1

公开(公告)日：2021-08-26

申请号：US16967664

申请日：2019-02-01

Applicant: Shanghai Haihe Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Lin Xia ,  Meiyu Geng ,  Yan Ye ,  Jian Ding ,  Qiong Zhang ,  Aijun Shen ,  Ying Huang ,  Hongchun Liu ,  Haoran Yang ,  Jing Ai ,  Minmin Zhang

IPC: C07D471/04 ,  C07D519/00 ,  C07D403/04 ,  C07D498/04 ,  C07D401/14 ,  C07D487/04 ,  C07D413/14

Abstract: The invention relates to the field of pharmaceutical chemistry. Specifically, the present invention relates to a series of BET (bromodomain and extra-terminal domain) inhibitors having a novel structure, particularly inhibitors targeting BRD4 (Bromodomain-containing protein 4), and a preparation method and use therefor. The structure thereof is shown in the following general formula (I). Said compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or crystal form thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition thereof can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.

公开(公告)号：US11834432B2

公开(公告)日：2023-12-05

申请号：US15998927

申请日：2017-02-17

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao Zhang ,  Meiyu Geng ,  Li Xing ,  Jing Ai ,  Zilan Song ,  Xia Peng ,  Wangting Gu ,  Jian Ding

IPC: C07D213/75 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61P35/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4433 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/44

CPC classification number: C07D401/12 ,  A61P35/00 ,  C07D213/75 ,  C07D403/12 ,  C07D405/12 ,  C07D413/14 ,  C07D417/14

Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.

公开(公告)号：US20220280541A1

公开(公告)日：2022-09-08

申请号：US17631814

申请日：2020-08-05

Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng ,  Guangqiang Sun ,  Xinyi Wang ,  Jing Zhang ,  Teng Feng

IPC: A61K31/702 ,  A61P25/28 ,  G01N33/68 ,  G01N33/58 ,  C12Q1/689 ,  G01N1/30

Abstract: The present invention relates to identification of a carbohydrate drug-sensitive patient in patients having Alzheimer's disease. The present invention provides a method for identifying a carbohydrate drug-sensitive patient in patients having Alzheimer's disease.

公开(公告)号：US10988456B2

公开(公告)日：2021-04-27

申请号：US16487385

申请日：2018-02-12

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Youhong Hu ,  Meiyu Geng ,  Wenming Ren ,  Jian Ding ,  Xiaocong Guan ,  Jing Ai ,  Lang Wang ,  Xia Peng ,  Yang Liu ,  Yang Dai ,  Limin Zeng

IPC: C07D401/12 ,  C07D405/14 ,  C07D403/12 ,  A61P35/00 ,  B01J31/24 ,  B01J27/122 ,  B01J31/30

Abstract: An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.

公开(公告)号：US10829491B2

公开(公告)日：2020-11-10

申请号：US16463868

申请日：2017-11-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao Zhang ,  Jian Ding ,  Hua Xie ,  Zilan Song ,  Yu Xue ,  Linjiang Tong ,  Meiyu Geng

IPC: C07D471/14 ,  A61P35/00 ,  C07D487/14 ,  A61K31/519 ,  A61P37/02 ,  A61P35/02 ,  A61P29/00

Abstract: The present disclosure relates to a Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method thereof and use thereof. The compounds of the present invention have good inhibitory activities against BTK at the molecular and cellular levels. Importantly, the compounds of the present invention have low activity against Ramos cells of normal human B lymphoma cells, and have high activity against BTK-sensitive human diffuse large B lymphoma TMD8 cells, indicating that these type of compounds with novel structural are highly selective, off-target phenomenon and corresponding side effects are low. Thus it is a selective inhibitor of BTK with development potential.

公开(公告)号：US10683278B2

公开(公告)日：2020-06-16

申请号：US15752896

申请日：2016-08-18

Applicant: JINAN UNIVERSITY ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ke Ding ,  Meiyu Geng ,  Li Tan ,  Jian Ding ,  Zhang Zhang ,  Jing Ai ,  Xiaomei Ren ,  Donglin Gao ,  Zhengchao Tu ,  Xiaoyun Lu ,  Dongmei Zhang

IPC: A61K31/4709 ,  C07D215/233 ,  C07D401/12 ,  C07D471/04 ,  C07D471/06 ,  C07D487/04 ,  C07D491/048 ,  C07D498/06 ,  C07D513/04 ,  C07D519/00

Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.